Literature DB >> 24366000

Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.

Dai Shimizu1, Mitsuro Kanda1, Shuji Nomoto1, Hisaharu Oya1, Hideki Takami1, Soki Hibino1, Masaya Suenaga1, Yoshikuni Inokawa1, Mitsuhiro Hishida1, Nao Takano1, Yoko Nishikawa1, Suguru Yamada1, Tsutomu Fujii1, Goro Nakayama1, Hiroyuki Sugimoto1, Masahiko Koike1, Michitaka Fujiwara1, Yasuhiro Kodera1.   

Abstract

Patients with hepatocellular carcinoma (HCC) have a poor prognosis, and novel molecular targets for treating recurrence and progression of the disease along with associated biomarkers are urgently required. In the present study, expression and the regulatory mechanism of TUSC1 (tumor suppressor candidate 1) were investigated to determine if it is a candidate tumor suppressor gene for HCC, which shows repressed transcription that involves aberrant DNA methylation. TUSC1 mRNA expression levels in HCC cell lines and 94 pairs of surgical specimens were determined using quantitative real-time reverse transcription polymerase chain reaction assay. Methylation status of HCC cell lines and clinical samples were analyzed to investigate the regulatory mechanism of TUSC1 transcription and the relationship between the methylation status of the TUSC1 gene and clinicopathological factors. The expression and distribution of the TUSC1 protein in liver tissues were determined using immunohistochemistry. A majority of HCC cell lines (89%) and surgical specimens (84%) demonstrated reduced expression levels of TUSC1 mRNA compared with paired non-cancerous liver tissues. The mean mRNA expression level in HCC was significantly lower than in corresponding non-cancerous liver. In contrast, no significant difference was found in TUSC1 mRNA expression level between adjacent normal and cirrhotic liver tissue from HCC patients. The TUSC1 protein expression pattern in HCC and liver tissues was consistent with TUSC1 mRNA expression. Twenty-nine (31%) of 94 patients showed intragenic hypermethylation of the TUSC1 gene in HCC, and hypermethylation was significantly associated with advanced pathological stage. Subsequently, patients with hypermethylation of the TUSC1 gene had a significantly poorer prognosis than patients without hypermethylation. Our results suggest that TUSC1 is a candidate tumor suppressor gene and intragenic hypermethylation is one of the suppressive mechanisms that regulate TUSC1 transcription in HCC. Intragenic methylation of the TUSC1 gene may serve as a novel prognostic marker of HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366000     DOI: 10.3892/or.2013.2939

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Arsenic-gene interactions and beta-cell function in the Strong Heart Family Study.

Authors:  Poojitha Balakrishnan; Ana Navas-Acien; Karin Haack; Dhananjay Vaidya; Jason G Umans; Lyle G Best; Walter Goessler; Kevin A Francesconi; Nora Franceschini; Kari E North; Shelley A Cole; V Saroja Voruganti; Matthew O Gribble
Journal:  Toxicol Appl Pharmacol       Date:  2018-04-03       Impact factor: 4.219

2.  Prognostic relevance of SAMSN1 expression in gastric cancer.

Authors:  Mitsuro Kanda; Dai Shimizu; Satoshi Sueoka; Shuji Nomoto; Hisaharu Oya; Hideki Takami; Kazuhiro Ezaka; Ryoji Hashimoto; Yuri Tanaka; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2016-10-06       Impact factor: 2.967

3.  Tumor Suppressor Candidate 1 Suppresses Cell Growth and Predicts Better Survival in Glioblastoma.

Authors:  Rui Zhang; Wan Yu; Guanyu Liang; Zhanjun Jia; Zhengxin Chen; Lin Zhao; Yongsheng Yuan; Xiaobin Zhou; Daqian Li; Shuying Shen; Ning Liu; Aihua Zhang; Huibo Wang; Gang Wang
Journal:  Cell Mol Neurobiol       Date:  2016-02-20       Impact factor: 5.046

Review 4.  Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.

Authors:  Maria Tampaki; George Vasileios Papatheodoridis; Evangelos Cholongitas
Journal:  Clin J Gastroenterol       Date:  2021-03-27

5.  Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor.

Authors:  Hisaharu Oya; Mitsuro Kanda; Hiroyuki Sugimoto; Dai Shimizu; Hideki Takami; Soki Hibino; Ryoji Hashimoto; Yukiyasu Okamura; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Masahiko Koike; Shuji Nomoto; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2014-08-31       Impact factor: 7.527

6.  Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.

Authors:  Alexey G Mittenberg; Valeria O Kuzyk; Sergey V Shabelnikov; Daria P Gorbach; Alla N Shatrova; Olga A Fedorova; Nickolai A Barlev
Journal:  Cell Cycle       Date:  2018-08-01       Impact factor: 4.534

Review 7.  Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.

Authors:  Mitsuro Kanda; Hiroyuki Sugimoto; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

8.  Association of TUSC1 and DPF3 gene polymorphisms with male infertility.

Authors:  Youichi Sato; Chise Hasegawa; Atsushi Tajima; Shiari Nozawa; Miki Yoshiike; Eitetsue Koh; Jiro Kanaya; Mikio Namiki; Kiyomi Matsumiya; Akira Tsujimura; Kiyoshi Komatsu; Naoki Itoh; Jiro Eguchi; Aiko Yamauchi; Teruaki Iwamoto
Journal:  J Assist Reprod Genet       Date:  2017-10-03       Impact factor: 3.412

9.  GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer.

Authors:  Dai Shimizu; Mitsuro Kanda; Haruyoshi Tanaka; Daisuke Kobayashi; Chie Tanaka; Masamichi Hayashi; Naoki Iwata; Yukiko Niwa; Hideki Takami; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

10.  Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer.

Authors:  Mitsuro Kanda; Shuji Nomoto; Hisaharu Oya; Dai Shimizu; Hideki Takami; Soki Hibino; Ryoji Hashimoto; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  J Exp Clin Cancer Res       Date:  2014-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.